Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmaceutical Sciences, Usmanu Danfodiyo University Sokoto, Sokoto, Nigeria.
Department of Pharmacy, Usmanu Danfodiyo University Teaching Hospital, Sokoto, Nigeria.
Ann Afr Med. 2024 Apr 1;23(2):125-131. doi: 10.4103/aam.aam_42_23. Epub 2023 Oct 30.
Over 1.6 million Nigerians have succumbed to the ravaging scourge of the acquired immunodeficiency syndrome (AIDS) epidemic since its discovery. Viral suppression (VS) then becomes a critical cost-effective human immunodeficiency virus (HIV) prevention strategy. We assessed the prevalence and predictors of VS.
This retrospective case file review was conducted among adults (aged ≥18 years) living with HIV/AIDS who accessed care at a tertiary health facility in Northwestern Nigeria between January and December 2021.
One thousand one hundred and twenty HIV/AIDS-eligible patients accessed care during the study. Their age ranged between 20 and 70 years with a mean of 43.83 ± 10.83 (95% confidence interval [CI]: 43.19-44.46). The patients were mostly female (728; 65.0), residing in urban areas (680; 60.7%), self-employed (440; 39.3%), married (712; 63.6%), receiving antiretroviral therapy (ART) for at most 14 years (916; 81.8%), on first-line ART regimen (812; 72.5%), in HIV clinical stage 1 (964; 86.1%), and with a baseline CD4 count of 199 cells/µl (453; 40.4%). The prevalence of VS of 64.3% (720/1120) was recorded in the study. The predictors of VS were disclosure of HIV status (odds ratio [OR] =2.4; 95% CI = 1.503-3.832), absence of opportunistic infections (OR = 2.6; 95% CI = 1.242-5.406), receiving ART for 15-29 years (OR = 2.1; 95% CI = 1.398-3.292), first-line ART regimen (OR = 3.7; 95% CI = 2.618-5.115), and adequate adherence (OR = 4.7; 95% CI = 3.324-6.766).
VS was suboptimal among the study cohort with adequate adherence being its strongest predictor.
自艾滋病（AIDS）发现以来，已有超过 160 万尼日利亚人死于这种肆虐的传染病。病毒抑制（VS）因此成为一种具有成本效益的关键人类免疫缺陷病毒（HIV）预防策略。我们评估了 VS 的流行率和预测因素。
这项回顾性病例档案研究在尼日利亚西北部一家三级医疗机构接受护理的年龄在 18 岁及以上的 HIV/AIDS 成年患者中进行。
在研究期间，有 1120 名符合 HIV/AIDS 条件的患者接受了治疗。他们的年龄在 20 岁至 70 岁之间，平均年龄为 43.83 ± 10.83（95%置信区间[CI]：43.19-44.46）。这些患者主要是女性（728 名，占 65.0%），居住在城市地区（680 名，占 60.7%），自雇（440 名，占 39.3%），已婚（712 名，占 63.6%），接受抗逆转录病毒疗法（ART）治疗时间不超过 14 年（916 名，占 81.8%），使用一线 ART 方案（812 名，占 72.5%），处于 HIV 临床阶段 1（964 名，占 86.1%），基线 CD4 计数为 199 个细胞/µl（453 名，占 40.4%）。在这项研究中，VS 的流行率为 64.3%（720/1120）。VS 的预测因素包括 HIV 状况的披露（比值比[OR] =2.4；95%CI = 1.503-3.832）、无机会性感染（OR = 2.6；95%CI = 1.242-5.406）、接受 ART 治疗 15-29 年（OR = 2.1；95%CI = 1.398-3.292）、一线 ART 方案（OR = 3.7；95%CI = 2.618-5.115）和充分的依从性（OR = 4.7；95%CI = 3.324-6.766）。
在接受治疗的研究队列中，VS 并不理想，充分的依从性是其最强的预测因素。
